[1] Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis.Clin Gastroenterol Hepatol, 2020,18(12):2650-2666. [2] Campbell KA, Trivedi HD, Chopra S. Infections in cirrhosis: a guide for the clinician.Am J Med, 2021,134(6):727-734. [3] Song KD, Choi SY, Heo NH, et al.Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: a retrospective case-control study.J Magn Reson Imaging, 2020,51(1):70-80. [4] Schicchi N, Fogante M, Esposto Pirani P, et al.Third-generation dual-source dual-energy CT in pediatric congenital heart disease patients: state-of-the-art. Radiol Med, 2019 ,124(12):1238-1252. [5] Pulickal GG, Singh D, Lohan R, et al. Dual-source dual-energy CT in submandibular sialolithiasis: reliability and radiation burden.Am J Roentgenol, 2019,213(6):1291-1296. [6] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.实用肝脏病杂志,2018,21(1):21-31. [7] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版). 中华消化外科杂志,2022,21(2):143-168. [8] Lee NY, Suk KT.The role of the gut microbiome in liver cirrhosis treatment.Int J Mol Sci, 2020, 22(1):199. [9] Trebicka J, Bork P, Krag A, et al.Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.Nat Rev Gastroenterol Hepatol, 2021, 18(3):167-180. [10] Zhuo S, Sun J, Chang J, et al.Dual-source dual-energy thin-section CT combined with small field of view technique for small lymph node in thyroid cancer: a retrospective diagnostic study.Gland Surg, 2021,10(4):1347-1358. [11] Ojha V, Verma M, Kumar S, et al.Imaging of the spectrum of abnormal systemic arterial supply to the lungs using dual-source CT.Clin Radiol, 2021,76(3):235. [12] 朱福成. 螺旋CT动脉三期扫描联合CTA技术对sPLC的诊断效果. 实用癌症杂志,2017,32(9):1486-1488. [13] Jung EM, Weber MA, Wiesinger I.Contrast-enhanced ultrasound perfusion imaging of organs.Radiology, 2021,61(1):19-28. [14] Zou M, Zhao Z, Zhang B, et al. Pulmonary lesions: correlative study of dynamic triple-phase enhanced CT perfusion imaging with tumor angiogenesis and vascular endothelial growth factor expression.BMC Med Imaging, 2021, 21(1):158. [15] Cheng Z, Wei-Qi J, Jin D.New insights on sorafenib resistance in liver cancer with correlation of individualized therapy.Biochim Biophys Acta Rev Cancer,2020 ,1874(1):188382. [16] Talaki E,Schaffellner S,Kniepeiss D,et al.CT perfusion imaging of the liver and the spleen in patients with cirrhosis:Is there a correlation between perfusion and portal venous hypertension? Eur Radiol,2017,27(10):4173-4180. [17] Sim HW, Knox J, Sim HW, et al. Hepatocellular carcinoma in the era of immunotherapy. Curr Probl Cancer, 2018,42(1):40-48. [18] Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: Review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol,2015,44(6):479-486. [19] Chaudhari VA, Khobragade K, Bhandare M, et al. Management of fibrolamellar hepatocellular carcinoma. Chin Clin Oncol, 2018, 7(5):51. [20] Hartke J, Johnson M, Ghabril M, et al. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol, 2017,34(2):153-159. [21] Wang L, Wang R, Zhang C,et al.Hepatic parenchyma and vascular blood flow changes after TIPS with spectral CT iodine density in HBV-related liver cirrhosis.Sci Rep,2021,11(1):10535. [22] 袁劲松,赵志伟,盛练. 高场强MRI对肝硬化退变结节和sPLC诊断与鉴别诊断价值研究. 中国CT和MRI杂志,2017,15(4):90-92. [23] Llovet JM, Brú C, Bruix J, et al. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 1999, 19(3):329-338. [24] 赵志雄,刘铁军,肖运平. 64排增强CT增强灌注成像对肝硬化、sPLC的临床诊断价值. 中国CT和MRI杂志,2021,19(6):99-102. |